PMID- 21168678
OWN - NLM
STAT- MEDLINE
DCOM- 20110425
LR  - 20101220
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 42
IP  - 10
DP  - 2010 Dec
TI  - Copeptin in relation to New York Heart Association class in heart transplant 
      recipients and kidney transplant recipients.
PG  - 4259-62
LID - 10.1016/j.transproceed.2010.09.031 [doi]
AB  - Copeptin is cosynthesized with vasopressin, also known as antidiuretic hormone. 
      It is more stable than vasopressin. Recently copeptin has been studied as a 
      diagnostic and prognostic marker for various diseases. Among patients with 
      destabilized heart failure, copeptin was an accurate prognostic marker for 
      mortality. Chronic heart failure is present in more than one-third of incident 
      dialysis patients as well as in kidney allograft recipients. The aim of this 
      study was to assess copeptin in orthotopic heart and kidney allograft recipients 
      in relation to New York Heart Association (NYHA) class and kidney function. The 
      studies were performed on 134 prevalent patients including 103 males and 31 
      females after orthotopic heart (OHT) and 80 prevalent kidney allograft recipients 
      including 51 males and 29 females. Glomerular filtration rate (GFR) was estimated 
      using the simplified MDRD and Chronic Kidney Disease Epidemiology Collaboration 
      (CKD-EPI) formulae. We measured complete blood count, urea, serum lipids, fasting 
      glucose, creatinine, NT-proBNP using standard methods in the central laboratory 
      of the hospital. Plasma copeptin, estimated using a commercially available kit, 
      was correlated with kidney function parameters of creatinine, estimated GFR by 
      MDRD and CKD-EPI, NT-proBNP and ejection fraction. Copeptin was significantly 
      lower among kidney allograft than orthotopic heart recipients: 0.71 +/- 0.13 ng/mL 
      versus 0.99 +/- 0.36 ng/mL (P < .001). Kidney allograft recipients were 
      significantly younger, with shorter times after transplantation, but similar 
      serum creatinine and estimated GFR values. Kidney allograft recipients displayed 
      lower NYHA classes. Copeptin was higher in chronic kidney disease stage 4 than 
      stage 2; similarly in NYHA class III versus I. However, these correlations did 
      not achieve statistical significance. There was no effect of gender, diabetes, or 
      hypertension on copeptin levels in either group of transplanted patients. Among 
      the heart transplant population copeptin is independently associated with kidney 
      and heart function, but not in kidney allograft recipients. It may also predict 
      outcomes of orthotopic heart transplant patients.
CI  - Copyright (c) 2010 Elsevier Inc. All rights reserved.
FAU - Malyszko, J
AU  - Malyszko J
AD  - Department of Nephrology and Transplantology, Medical University, Bialystok, 
      Poland.
FAU - Przybylowski, P
AU  - Przybylowski P
FAU - Koc-Zorawska, E
AU  - Koc-Zorawska E
FAU - Iaina-Levin, N
AU  - Iaina-Levin N
FAU - Sadowski, J
AU  - Sadowski J
FAU - Mysliwiec, M
AU  - Mysliwiec M
FAU - Malyszko, J S
AU  - Malyszko JS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Glycopeptides)
RN  - 0 (copeptins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Glycopeptides/*blood
MH  - *Heart Transplantation
MH  - Humans
MH  - Kidney Failure, Chronic/blood/physiopathology
MH  - *Kidney Transplantation
MH  - Male
MH  - Middle Aged
MH  - *Societies, Medical
EDAT- 2010/12/21 06:00
MHDA- 2011/04/26 06:00
CRDT- 2010/12/21 06:00
PHST- 2010/08/19 00:00 [received]
PHST- 2010/09/03 00:00 [accepted]
PHST- 2010/12/21 06:00 [entrez]
PHST- 2010/12/21 06:00 [pubmed]
PHST- 2011/04/26 06:00 [medline]
AID - S0041-1345(10)01357-6 [pii]
AID - 10.1016/j.transproceed.2010.09.031 [doi]
PST - ppublish
SO  - Transplant Proc. 2010 Dec;42(10):4259-62. doi: 
      10.1016/j.transproceed.2010.09.031.